Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)
01-12-20072. REPORT TYPE (From -To)
Annual
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERInstitute for Cancer Research Philadelphia, PA 19111
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTIncreased genomic instability arising from centrosomal amplification has been proposed to be an important factor causing development of traits associated with highly malignant ovarian tumors, including multidrug resistance and increased tendency to metastasis. This proposal addresses the hypothesized interaction between the Cas proteins (HEF1 and p130Cas), Aurora A (AurA) and Ajuba as being likely to contribute to genomic instability and metastatic properties of ovarian tumors. Our work in the second project period has defined and performed detailed analysis of the HEF1-AurA-Ajuba complex. This has allowed us to develop a model in which HEF1 and AurA mutually stabilize each other, and HEF1 and Ajuba synergize to promote AurA activation at mitotic entry. At mitotic exit, phosphorylation by AurA promotes HEF1 return to focal adhesions. Excess of HEF1 protects AurA from inhibition by targeted small molecule inhibitors. In the past two years, elevation of HEF1 has been established as important for metastasis and/or invasion in lung cancer, melanoma, and glioblastoma; our ongoing work on this project will determine whether this is also true for ovarian cancer.
SUBJECT TERMSHEF1, Aurora-A, NEDD9, Ajuba Golemis, Erica
INTRODUCTION:The goal of this proposal is to better understand factors leading to ovarian cancer development, with the intent of improving diagnosis and treatment for ovarian cancer. Our preliminary data defined the HEF1 member of the Cas protein family as a regulator of centrosomal dynamics and genomic instability through control of the Aurora A (AurA) kinase. Th...